15 completed, 5 terminated, 5 unknown, 1 no longer available. 16 Phase 1, 9 Phase 2, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Completed 9, Unknown 5, Terminated 1, Withdrawn 1 |
| Phase 2 | 9 | Completed 5, Terminated 3, Unknown 1 |
| Phase 3 | 4 | Completed 3, Terminated 1 |
Follow Threshold Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunotherapy Study of Evofosfamide in Combination With Ipilimumab Evofosfamide, Ipilimumab - Pancreatic Cancer, Melanoma | Phase 1 | Unknown | Threshold Pharmaceuticals | 69 | 2017-05-10 | 2017-10-30 |
| Testing TH-302, in Combination With Preoperative Chemoradiotherapy, in Esophageal Cancer. TH-302, HX4 scan, Carboplatin - Esophageal Cancer | Phase 1 | Withdrawn | Maastricht Radiation Oncology | 2015-12-01 | 2016-04-21 | |
| A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours TH-302 + Sunitinib - Neuroendocrine Tumors, Pancreatic Neoplasms | Phase 2 | Completed | Grupo Espanol de Tumores Neuroendocrinos | 17 | 2015-05-11 | 2020-07-27 |
| Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer TH-302 monotherapy - Biliary Tract Cancer | Phase 2 | Completed | Seoul National University Hospital | 24 | 2015-04-01 | 2018-09-10 |
| A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma TH-302, Doxorubicin - Soft Tissue Sarcoma | Phase 2 | Terminated | Merck KGaA, Darmstadt, Germany | 6 | 2014-12-10 | 2018-12-14 |
| TH-302 Plus Doxorubicin Delivered by Trans-Arterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma Phase I Dose level -1, Phase I dose level 1, Phase I Dose level 2 - Hepatocellular Carcinoma | Phase 1 | Unknown | Scripps Clinic Cancer Center | 20 | 2014-12-01 | 2014-07-04 |
| A Phase 1 TH-302 Mass Balance Trial [14C] TH-302 (Label 1), [14C] TH-302 (Label 2), Unlabeled TH-302 - Solid Tumor | Phase 1 | Completed | Merck KGaA, Darmstadt, Germany | 10 | 2014-02-01 | 2016-06-10 |
| Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer TH-302, Nab-paclitaxel, Gemcitabine - Pancreatic Cancer | Phase 1 | Terminated | ImmunoGenesis | 19 | 2014-01-01 | 2025-05-11 |
| A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors TH-302 - Solid Tumors | Phase 1 | Unknown | Threshold Pharmaceuticals | 40 | 2013-11-01 | 2016-06-02 |
| A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer Evofosfamide, Gemcitabine - Solid Tumor, Pancreatic Cancer | Phase 1 | Completed | Merck KGaA, Darmstadt, Germany | 20 | 2013-04-18 | 2018-10-15 |
| Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma TH-302, Gemcitabine, Placebo (5 percent dextrose - D5W) - Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma | Phase 3 | Completed | ImmunoGenesis | 693 | 2012-12-01 | 2025-05-11 |
| Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery hypoxia-activated prodrug TH-302, sorafenib tosylate - Kidney Cancer, Liver Cancer | Phase 1 | Completed | Alliance for Clinical Trials in Oncology | 24 | 2012-05-01 | 2020-02-06 |
| Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma TH-302, TH-302 and Dexamethasone, TH-302 Dose Escalation and Dexamethasone in Combination with Bortezomib - Multiple Myeloma | Phase 1 / Phase 2 | Unknown | Threshold Pharmaceuticals | 98 | 2012-02-01 | 2016-06-02 |
| Dose Escalation Study of Pazopanib Plus TH-302 Pazopanib and TH-302 - Solid Tumors | Phase 1 | Completed | Herbert Hurwitz, MD | 50 | 2011-12-01 | 2017-09-01 |
| A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma TH-302 in Combination with Doxorubicin, Doxorubicin - Soft Tissue Sarcoma | Phase 3 | Completed | Threshold Pharmaceuticals | 640 | 2011-09-01 | 2016-06-02 |
| Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors TH-302 - Advanced Renal Cell Carcinoma, Gastrointestinal Stromal Tumors | Phase 1 | Unknown | Threshold Pharmaceuticals | 58 | 2011-06-01 | 2014-04-21 |
| Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias TH-302 - Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia | Phase 1 | Completed | Threshold Pharmaceuticals | 40 | 2010-06-01 | 2015-05-07 |
| Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors TH-302 - Non-Small Cell Lung Cancer, Prostate Cancer | Phase 1 / Phase 2 | Completed | Threshold Pharmaceuticals | 71 | 2008-08-01 | 2015-05-07 |
| A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors TH-302 - Tumors, Hypoxia | Phase 1 | Completed | Threshold Pharmaceuticals | 129 | 2007-06-01 | 2012-07-27 |
| Safety and Efficacy Study of Glufosfamide in Previously Treated Advanced Soft Tissue Sarcoma Glufosfamide - Soft Tissue Sarcoma | Phase 2 | Completed | Eleison Pharmaceuticals LLC. | 22 | 2007-03-01 | 2015-03-25 |
Showing 20 of 27. Sign in to see all of them.
Pancreatic Neoplasms (9) · Hypoxia (4) · Neoplasms (4) · Sarcoma (4) · Neoplasm Metastasis (3) · Carcinoma, Hepatocellular (2) · Liver Neoplasms (2) · Neuroectodermal Tumors, Primitive (2) · Prostatic Hyperplasia (2) · Prostatic Neoplasms (2) · Biliary Tract Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Esophageal Neoplasms (1)
TH 302 (18) · Gemcitabine (4) · beta-D-glucosylisophosphoramide mustard (4) · Doxorubicin (2) · lonidamine (2) · 130-nm albumin-bound paclitaxel (1) · Bortezomib (1) · Carboplatin (1) · Deoxyglucose (1) · Dexamethasone (1) · Ipilimumab (1) · Paclitaxel (1) · Radiotherapy (1) · Sorafenib (1) · Sunitinib (1)
United States (19) · Germany (4) · Hungary (3) · Brazil (2) · Italy (2) · Japan (2) · Poland (2) · Russia (2) · Spain (2) · Argentina (1) · Austria (1) · Belgium (1) · Bulgaria (1) · Canada (1) · Czechia (1)
Lee Cranmer, MD, PhD (2) · Alexander Starodub, MD (1) · Antonio Gualberto, MD, PhD (1) · Claire Verschraegen, MD (1) · Darren S Sigal, MD (1) · David Hong, MD (1) · David Mendelson, MD (1) · Do-Youn Oh, MD, PhD (1) · Douglas Adkins, MD (1) · Enrique Grande, MD (1) · Gerald Rosen, MD (1) · Gerold Bepler, MD, PhD (1) · Gina D'Amato, MD (1) · Glen Weiss, MD (1)
PMID 25512461, PMID 23228990, PMID 25185097, PMID 25679067, PMID 27535748, PMID 28651927, PMID 34190375
2014 (1), U10CA031946 (1)